Skip to main content
MPLT
NASDAQ Life Sciences

MapLight Therapeutics Completes Enrollment for Two Phase 2 Trials, Reports Q1 Results

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$29.29
Mkt Cap
$1.243B
52W Low
$12.24
52W High
$33.28
52W Position info
139% above low
Off High info
12% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

MPLT has more than doubled off its 52-week low of $12.24.

Summary

MapLight Therapeutics announced the completion of enrollment for its Phase 2 ZEPHYR and IRIS trials, with topline results anticipated by mid-August 2026, alongside Q1 2026 financial results and a reaffirmed cash runway through 2027.


Key Events · Product Development and Regulatory · MPLT

  • Phase 2 Enrollment Completed

    Enrollment has been completed for ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia (307 participants) and ML-004's Phase 2 IRIS trial in autism spectrum disorder (161 participants).

  • Upcoming Topline Results

    Topline results for both the ZEPHYR and IRIS trials are expected by mid-August 2026, representing significant near-term catalysts.

  • Q1 2026 Financials Reported

    The company reported a net loss of $60.7 million for the first quarter of 2026, an increase from $22.3 million in Q1 2025, with R&D expenses rising to $53.7 million.

  • Cash Runway Extended Through 2027

    MapLight Therapeutics ended Q1 2026 with $395.2 million in cash, cash equivalents, and investments, which is expected to fund operations through 2027.


Analysis · MPLT · Life Sciences

This 8-K highlights significant clinical progress for MapLight Therapeutics, with the completion of enrollment for two key Phase 2 trials (ZEPHYR for schizophrenia and IRIS for autism spectrum disorder). Topline results for both are expected by mid-August 2026, representing major near-term catalysts for the company. While the company reported an increased net loss for Q1 2026, its cash position of $395.2 million is expected to fund operations through 2027, providing a stable financial runway ahead of these critical data readouts.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MPLT was trading at $29.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.24 to $33.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MPLT - Latest Insights

MPLT
Nov 16, 2026, 7:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $6.64 info
Change: -$0.730 (-10%) info
Market Cap: $369.579M info
MPLT
Nov 16, 2026, 7:20 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.37
Real-time Price: $6.64 info
Change: -$0.730 (-10%) info
Market Cap: $369.579M info
MPLT
Nov 16, 2026, 7:15 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $6.64 info
Change: -$0.610 (-8%) info
Market Cap: $369.579M info
MPLT
Aug 18, 2026, 6:55 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $11.59
Real-time Price: $6.64 info
Change: -$4.95 (-43%) info
Market Cap: $369.579M info
MPLT
Aug 18, 2026, 6:51 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.59
Real-time Price: $6.64 info
Change: -$4.95 (-43%) info
Market Cap: $369.579M info